Belpointe Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.7M | Buy |
46,672
+3,297
| +8% | +$709K | 0.38% | 47 |
|
|
2026
Q1 | $9.43M | Buy |
43,375
+7,840
| +22% | +$1.74M | 0.34% | 54 |
|
|
2025
Q4 | $8.12M | Sell |
35,535
-113
| -0.3% | -$25.7K | 0.29% | 60 |
|
|
2025
Q3 | $8.25M | Buy |
35,648
+2,618
| +8% | +$533K | 0.32% | 61 |
|
|
2025
Q2 | $6.13M | Sell |
33,030
-1,595
| -5% | -$296K | 0.26% | 69 |
|
|
2025
Q1 | $7.25M | Sell |
34,625
-4,903
| -12% | -$953K | 0.38% | 43 |
|
|
2024
Q4 | $7.76M | Sell |
39,528
-242
| -0.6% | -$44.5K | 0.47% | 36 |
|
|
2024
Q3 | $7.85M | Buy |
39,770
+2,062
| +5% | +$385K | 0.47% | 34 |
|
|
2024
Q2 | $6.47M | Buy |
37,708
+1,010
| +3% | +$167K | 0.45% | 39 |
|
|
2024
Q1 | $6.68M | Buy |
36,698
+2,148
| +6% | +$370K | 0.5% | 33 |
|
|
2023
Q4 | $5.35M | Buy |
34,550
+403
| +1% | +$58.8K | 0.47% | 37 |
|
|
2023
Q3 | $5.09M | Buy |
34,147
+971
| +3% | +$143K | 0.53% | 31 |
|
|
2023
Q2 | $4.47M | Sell |
33,176
-25,476
| -43% | -$3.74M | 0.47% | 35 |
|
|
2023
Q1 | $9.35M | Sell |
58,652
-2,366
| -4% | -$362K | 0.5% | 30 |
|
|
2022
Q4 | $9.86M | Buy |
61,018
+4,807
| +9% | +$737K | 0.6% | 24 |
|
|
2022
Q3 | $7.54M | Buy |
56,211
+10,423
| +23% | +$1.5M | 0.51% | 34 |
|
|
2022
Q2 | $7.01M | Sell |
45,788
-9,900
| -18% | -$1.51M | 0.47% | 32 |
|
|
2022
Q1 | $9.03M | Sell |
55,688
-11,610
| -17% | -$1.69M | 0.55% | 25 |
|
|
2021
Q4 | $9.11M | Buy |
67,298
+1,474
| +2% | +$174K | 0.57% | 24 |
|
|
2021
Q3 | $7.1M | Buy |
65,824
+12,164
| +23% | +$1.39M | 0.48% | 27 |
|
|
2021
Q2 | $6.04M | Buy |
53,660
+2,642
| +5% | +$298K | 0.44% | 35 |
|
|
2021
Q1 | $5.52M | Sell |
51,018
-6,547
| -11% | -$700K | 0.47% | 30 |
|
|
2020
Q4 | $6.17M | Buy |
57,565
+3,145
| +6% | +$302K | 0.55% | 28 |
|
|
2020
Q3 | $4.77M | Sell |
54,420
-8,829
| -14% | -$831K | 0.53% | 33 |
|
|
2020
Q2 | $6.21M | Buy |
63,249
+31,762
| +101% | +$2.8M | 0.8% | 21 |
|
|
2020
Q1 | $2.4M | Sell |
31,487
-1,848
| -6% | -$157K | 0.42% | 46 |
|
|
2019
Q4 | $2.95M | Buy |
33,335
+5,991
| +22% | +$497K | 0.37% | 63 |
|
|
2019
Q3 | $2.07M | Buy |
27,344
+3,589
| +15% | +$246K | 0.34% | 68 |
|
|
2019
Q2 | $1.73M | Sell |
23,755
-597
| -2% | -$46.9K | 0.34% | 60 |
|
|
2019
Q1 | $1.96M | Buy |
24,352
+103
| +0.4% | +$8.43K | 0.38% | 46 |
|
|
2018
Q4 | $2.24M | Buy |
24,249
+4,342
| +22% | +$382K | 0.57% | 24 |
|
|
2018
Q3 | $1.88M | Sell |
19,907
-943
| -5% | -$89.4K | 0.3% | 61 |
|
|
2018
Q2 | $1.93M | Sell |
20,850
-1,248
| -6% | -$122K | 0.54% | 24 |
|
|
2018
Q1 | $2.09M | Sell |
22,098
-7,702
| -26% | -$846K | 0.61% | 22 |
|
|
2017
Q4 | $2.88M | Buy |
29,800
+5,503
| +23% | +$519K | 0.63% | 24 |
|
|
2017
Q3 | $2.16M | Buy |
+24,297
| New | +$1.85M | 0.51% | 35 |
|
Other funds holding ABBV
Belpointe Asset Management's ABBV Position: Q2 2026 in Review
Belpointe Asset Management increased its AbbVie (ABBV) stake by 7.6% in Q2 2026, buying an estimated $709K and bringing the position to 46,672 shares worth $11.7M. The position accounts for 0.38% of the portfolio, ranked #47.
Belpointe Asset Management first reported a position in ABBV in Q3 2017 and has held it in 36 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Belpointe Asset Management held 46,672 shares of AbbVie worth $11.7M as of Q2 2026.
- Belpointe Asset Management bought 3,297 AbbVie shares in Q2 2026, an estimated $709K.
- AbbVie made up 0.38% of Belpointe Asset Management's portfolio in Q2 2026, its #47 holding.
- Belpointe Asset Management first reported a position in AbbVie in Q3 2017 and has held it in 36 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.